Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
11 studies found for:    19717844 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Stroke Prevention and Rhythm Interventions in Atrial Fibrillation
Condition: Cardiovascular Diseases
Intervention:
2 Terminated
Has Results
Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively
Condition: Primary Disease
Interventions: Drug: Dabigatran;   Drug: Warfarin
3 Unknown  Safety Study of Dabigatran in CADASIL
Condition: CADASIL
Interventions: Drug: Dabigatran;   Drug: Antiplatelets
4 Recruiting Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation
Condition: Atrial Fibrillation and Flutter
Intervention: Other: New oral anticoagulant pharmacodynamic analysis (blood level assesment)
5 Recruiting Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
Condition: Atrial Fibrillation
Interventions: Drug: Dabigatran etexilate;   Drug: Rivaroxaban;   Drug: Apixaban
6 Recruiting Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?
Condition: Acute Kidney Injury
Intervention:
7 Recruiting Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
Conditions: Coronary Artery Bypass Grafting;   Postoperative Atrial Fibrilation;   Stroke;   Systemic Embolism;   Deep Venous Thrombosis
Interventions: Drug: Apixaban;   Drug: Warfarin
8 Recruiting Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
Condition: Atrial Fibrillation
Interventions: Drug: NOAC;   Device: Left atrial appendage closure
9 Recruiting Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome
Conditions: Antiphospholipid Syndrome;   Thrombosis
Interventions: Drug: Apixaban;   Drug: Warfarin
10 Completed
Has Results
Genetic Response to Warfarin in Healthy Subjects
Condition: Healthy
Intervention: Drug: Warfarin
11 Completed
Has Results
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Conditions: Atrial Fibrillation;   Stroke
Interventions: Drug: warfarin;   Drug: Dabigatran dose 1;   Drug: Dabigatran dose 2

Study has passed its completion date and status has not been verified in more than two years.